Prothena reported $295.38M in Cash and Equivalent for its fourth fiscal quarter of 2020.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Adamas Pharmaceuticals ADMS:US $ 71.66M 20.86M
Amgen AMGN:US $ 6266M 2821M
Biogen BIIB:US $ 1331.2M 893.6M
Bluebird Bio BLUE:US $ 317.7M 6.46M
Five Prime Therapeutics FPRX:US $ 36.02M 22.69M
Gw Pharmaceuticals GWPH:US $ 480.33M 2.77M
Prothena PRTA:US $ 295.38M 19.14M
Vertex Pharmaceuticals VRTX:US $ 5988.19M 630.1M
Vital Therapies VTL:US $ 48.61M 30.03M